404 related articles for article (PubMed ID: 25148578)
1. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD
Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
5. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
6. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
8. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Jahn SW; Kashofer K; Halbwedl I; Winter G; El-Shabrawi-Caelen L; Mentzel T; Hoefler G; Liegl-Atzwanger B
Mod Pathol; 2015 Jul; 28(7):895-903. PubMed ID: 25769001
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
11. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
12. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
13. Mutational profiling of acral melanomas in Korean populations.
Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
[TBL] [Abstract][Full Text] [Related]
14. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
15. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
16. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
[TBL] [Abstract][Full Text] [Related]
17. Mutational Profile of Driver Genes in Brazilian Melanomas.
Vicente ALSA; Crovador CS; Macedo G; Scapulatempo-Neto C; Reis RM; Vazquez VL
J Glob Oncol; 2019 Nov; 5():1-14. PubMed ID: 31756131
[TBL] [Abstract][Full Text] [Related]
18. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
19. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
20. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
